“…Twenty studies included only patients admitted to the ICU [ 21 , 23 , 25 , 26 , 28 , 31 – 33 , 36 – 40 , 44 – 48 , 53 , 54 ], five studies included patients admitted to a COVID-19-dedicated HDU [ 29 , 30 , 34 , 35 , 43 ], eight studies included patients who were admitted to both HDU and ICU [ 22 , 24 , 27 , 41 , 42 , 49 , 50 , 52 ], and one study included Emergency Department patients who were later admitted either to ICU [ 51 ]. Thirty-one studies included data about patients who received vs. patients who did not receive vasopressors [ 21 – 38 , 40 – 49 , 51 , 53 , 54 ] and were included in review. Moreover, three studies included patients who received angiotensin-II [ 39 , 50 , 52 ] and, out of those, two compared the use of angiotensin-II with other vasopressors [ 50 , 52 ] (Additional file 3 : Appendix C2).…”